BI Sky Global Hits Major Landmark With Successful FDA MoCRA Approval

Innocan Pharma Corporation, a leading name in the pharmaceutical and biotechnology sectors, proudly reports that its subsidiary, BI Sky Global (BI), has successfully registered all its products under the FDA's Modernization of Cosmetics Regulation Act of 2022 (MoCRA).

Following a comprehensive assessment of BI's manufacturing processes and raw materials, the FDA confirmed that all products met its strict quality criteria, completing the MoCRA registration process. MoCRA requires all facilities involved in the production and processing of cosmetic products intended for sale in the U.S. to register with the FDA, ensuring adherence to stringent quality standards and allowing only top-tier cosmetic brands to enter the U.S. market.

Roni Kamhi, CEO of BI Sky Global, said in a statement, “Successful registration of our products and fully meeting the FDA's stringent standards is a significant milestone for us, which ensures our continued retail presence in the U.S. It very much demonstrates our commitment to the highest of standards and aligns with our mission to bring top quality products to the market.”